Chemotherapy-Related Hearing Loss in Pediatric Patients

A new study from Saarland University Hospital reveals that hearing damage from a common chemotherapy drug begins at much higher pitches than previously monitored. The research, led by Dietmar Hecker and colleagues, demonstrates that a specific hearing test can catch this damage earlier and more reliably in children, potentially safeguarding their development after cancer.

**The Challenge of Detecting “Silent” Hearing Loss**

Platinum-based chemotherapy drugs like cisplatin are highly effective against many childhood cancers. A well-known side effect is permanent sensory hearing loss, caused by damage to the outer hair cells in the inner ear. This damage typically starts in the high-frequency range, above 4-8 kHz, and progresses. For children, the consequences are severe. Hearing loss directly impacts speech perception, classroom learning, social integration, and overall personality development.

Conventional monitoring uses pure-tone audiometry (PTA), where a patient indicates when they hear a series of beeps. In the hectic, often stressful environment of pediatric oncology, this test is challenging. It requires active cooperation and concentration, which young, fatigued, or very ill children may not be able to provide. Furthermore, standard clinical PTA often stops at 8 kHz, missing the ultra-high frequencies where damage may first appear.

**DPOAE Testing: A More Feasible and Sensitive Tool**

The research team compared ultra-high frequency PTA (up to 16 kHz) with Distortion Product Otoacoustic Emission (DPOAE) measurements over the same range. DPOAE is an objective, non-invasive test. It places a small probe in the ear canal that plays two tones and measures the faint acoustic echoes produced by healthy outer hair cells in response. It doesn’t require the child to respond verbally or press a button.

In 83 pediatric cancer patients (aged 2-19 years) receiving cisplatin, carboplatin, or vincristine, the difference in feasibility was stark. Out of 153 examination sessions, only 60 PTA tests yielded reliable results. In contrast, all 153 DPOAE examinations produced informative data. “DPOAE measurement is more feasible and reliable,” the authors state plainly in their paper published in *Scientific Reports* [DOI: 10.1038/s41598-026-47642-z](https://doi.org/10.1038/s41598-026-47642-z).

**Cisplatin’s Signature: High-Frequency Loss and a Low-Frequency Signal**

The findings provided a clear picture of ototoxicity. Treatment with vincristine and carboplatin did not result in substantial hearing loss. The cisplatin group, however, showed a distinct pattern.

The most significant hearing loss was detected in the ultra-high frequencies between 10 and 16 kHz, visible in both PTA and DPOAE. DPOAE levels were significantly reduced from 13 to 16 kHz. This confirms that damage begins at the extreme high end of the hearing range, an area standard tests ignore.

A second, unexpected finding emerged. At the lower frequencies of 2.5 kHz and 3 kHz, the researchers observed a significant *increase* in DPOAE levels in cisplatin patients. This paradoxical boost could represent a compensatory mechanism or a stress response from the hair cells before they degenerate. It highlights the complex physiology of ototoxicity and suggests DPOAE might detect very early cellular changes before actual hearing loss occurs. This objective, physiological measure could complement other diagnostic approaches, such as the machine learning models being developed for hearing disorders.

**Implications for Pediatric Oncology and Auditory Health**

This study has direct practical implications for clinical care. The superior reliability of DPOAE testing in children makes it a strong candidate for routine ototoxicity monitoring programs. Its ability to detect damage in the 10-16 kHz range offers a critical early warning system.

“Early reliable detection of hearing loss may prompt attending oncologists to change chemotherapy if a less ototoxic therapeutic alternative is available,” the authors write. This could mean adjusting the dose, switching to a different platinum agent like carboplatin (which showed less ototoxicity in this study), or employing more aggressive protective strategies during treatment.

Protecting hearing in childhood cancer survivors is an investment in their quality of life. Undetected high-frequency loss can make it difficult to understand speech in noisy environments like classrooms, leading to educational delays and social isolation. Early intervention with hearing aids or classroom accommodations can mitigate these effects. For some survivors who later develop sound sensitivity conditions like hyperacusis, a clear audiological history is essential for management. Understanding the different brain responses in hyperacusis compared to other conditions starts with precise hearing data.

The research by Hecker and his team shifts the focus for monitoring ototoxicity higher and earlier. By adopting DPOAE testing into pediatric oncology protocols, clinicians can better shield a child’s hearing—and their future—from the collateral damage of essential, life-saving treatment.